WO2026114473 - A NEW METHOD TO USE A PATHOGEN TO GENERATE A VACCINE FOR ANOTHER PATHOGEN
National phase entry is expected:
Publication Number
WO/2026/114473
Publication Date
04.06.2026
International Application No.
PCT/EG2025/050038
International Filing Date
25.11.2025
Title **
[English]
A NEW METHOD TO USE A PATHOGEN TO GENERATE A VACCINE FOR ANOTHER PATHOGEN
[French]
NOUVEAU PROCÉDÉ D'UTILISATION D'UN AGENT PATHOGÈNE POUR PRODUIRE UN VACCIN POUR UN AUTRE AGENT PATHOGÈNE
Applicants **
MEHESIN, Maamoun osman mohamed
Inventors
MEHESIN, Maamoun osman mohamed
Priority Data
EG/P/2024/1591
28.11.2024
EG
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EGPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2072 | |
| EPO | Filing, Examination, Granting | 8683 | |
| Japan | Filing, Examination, Granting | 2122 | |
| South Korea | Filing, Examination, Granting | 2071 | |
| USA | Filing, Examination, Granting | 7740 |
Total:
22,688
Contact Us
Abstract[English]
We developed a new method to cure immunodeficiency diseases and fulfill all requirements for functional treatment without stimulating any immune-related adverse events by using a non-replicating viral vector that does not infect humans We developed the method whereby a vaccine is obtained using a pathogen and it is used to provide a full functional treatment for the disease of a different pathogen through the concept of boosting the defenses of the immune system sufficiently and only sufficiently To provide this full functional cure.